Dostarlimab vs Sintilimab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: PD-1 · full Non-Small Cell Lung Cancer pipeline

Dostarlimab

Marketed by GlaxoSmithKline and partners

Phase 3 in Non-Small Cell Lung Cancermonoclonal antibody
Partial signal

NCT04655976 · Phase 2/3 · active, not recruiting

Patients were randomly assigned to three arms (758 enrolled) with docetaxel as the active comparator, but the study was open label, with no masking. The primary endpoint, overall survival, was not significantly improved by dostarlimab plus docetaxel (HR 0.96, 95% CI 0.77 to 1.20, p=0.37) or by the triplet with cobolimab (HR 0.85, 95% CI 0.68 to 1.06, p=0.08), so the primary comparisons were not met.

Next expected readout: January 2027 · NCT06879717 (registry estimate)

Reported efficacy

Overall Survival (OS) (Arm A Versus Arm C) (Up to approximately 234 weeks); Overall Survival (OS) (Arm B Versus Arm C) (Up to approximately 234 weeks): Overall Survival (OS) (Arm A Versus Arm C) (Up to approximately 234 weeks): Cobolimab + Dostarlimab + Docetaxel (Arm A) 11.9 Months (95% CI 10.6 to 14.2) vs Docetaxel (Arm C) 11.3 Months (95% CI 9.5 to 13.9) (missed)

Result source: NCT04655976

Sintilimab

Marketed by Innovent Biologics and partners

Phase 3 in Non-Small Cell Lung Cancermonoclonal antibody
Partial signal

NCT03607539 · Phase 3 · completed

This trial was randomized, quadruple-blinded, and placebo-controlled with a reasonably large sample (397 patients) and used a hard clinical primary endpoint (progression-free survival), which is a strong design overall. However, the results record reports only median PFS values and confidence intervals for each arm (8.9 vs 5.0 months) without a p-value or hazard ratio, so whether the primary comparison reached statistical significance cannot be confirmed from the data provided.

Next expected readout: November 2026 · NCT05429463 (registry estimate)

Reported efficacy

Overall Survival (Through database cutoff date of 31-July-2020 (up to approximately 35 months)): Overall survival: sintilimab median 11.79 vs docetaxel 8.25 months (HR 0.74, 95% CI 0.56 to 0.96, P=0.025) (ORIENT-3, Cancer Commun 2022). (met)

Result source: NCT03150875

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointDostarlimabSintilimab
PFS, median4.4 vs 4.1vs Docetaxeln 305NCT04655976
2 other results
8.9 vs 5+3.9 vs placebon 266NCT03607539
2 other results
OS, median11.9 vs 11.3vs Docetaxeln 305NCT04655976
3 other results
11.8 vs 8.3vs Docetaxeln 145NCT03150875
ORR18.7% vs 14.5%vs Docetaxeln 305NCT04655976
2 other results
51.9% vs 29.8%+22.1 vs placebon 266NCT03607539
2 other results
  • 44.7% vs 35.4% n 179 · Phase 3 · secondary NCT03629925
  • 25.5% vs 2.2% n 145 · Phase 3 · secondary NCT03150875
Duration of response, median8.3 vs 8.8vs Docetaxeln 57NCT04655976
2 other results
6.0 vs 5.1+1 vs placebon 80NCT03629925
1 other result

PFS, median

Dostarlimab
4.4 vs 4.1vs Docetaxeln 305NCT04655976
2 other results
Sintilimab
8.9 vs 5+3.9 vs placebon 266NCT03607539
2 other results

OS, median

Dostarlimab
11.9 vs 11.3vs Docetaxeln 305NCT04655976
3 other results
Sintilimab
11.8 vs 8.3vs Docetaxeln 145NCT03150875

ORR

Dostarlimab
18.7% vs 14.5%vs Docetaxeln 305NCT04655976
2 other results
Sintilimab
51.9% vs 29.8%+22.1 vs placebon 266NCT03607539
2 other results
  • 44.7% vs 35.4% n 179 · Phase 3 · secondary NCT03629925
  • 25.5% vs 2.2% n 145 · Phase 3 · secondary NCT03150875

Duration of response, median

Dostarlimab
8.3 vs 8.8vs Docetaxeln 57NCT04655976
2 other results
Sintilimab
6.0 vs 5.1+1 vs placebon 80NCT03629925
1 other result
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Dostarlimab: 3 of 4 rows · Sintilimab: 2 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricDostarlimabSintilimab
Dropout rate
25.6%Cobolimab + Dostarlimab + Docetaxea
NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3
show 3 more results
21.6%Dostarlimab + Docetaxel (Arm B)
NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3
—Stage 2 (Cohort 1A): Niraparib + T
NCT03308942 · Phase 2 · registry result, not featured evidence · combination
—Stage 2 (Cohort 2A): Niraparib + T
NCT03308942 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestoneb
NCT03607539 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
show 2 more results
n/a: no completion milestone
NCT03150875 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
n/a: no completion milestone
NCT03629925 · Phase 3 · registry result, not featured evidence · combination
Discontinued due to AEs
—Cobolimab + Dostarlimab + Docetaxea
NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3
show 3 more results
—Dostarlimab + Docetaxel (Arm B)
NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3
—Stage 2 (Cohort 1A): Niraparib + T
NCT03308942 · Phase 2 · registry result, not featured evidence · combination
—Stage 2 (Cohort 2A): Niraparib + T
NCT03308942 · Phase 2 · registry result, not featured evidence · combination
—b
NCT03607539 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
show 2 more results
—
NCT03150875 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
—
NCT03629925 · Phase 3 · registry result, not featured evidence · combination
Serious AEs
33.8%Cobolimab + Dostarlimab + Docetaxea
NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3
show 3 more results
42.7%Dostarlimab + Docetaxel (Arm B)
NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3
58.3%Stage 2 (Cohort 1A): Niraparib + T
NCT03308942 · Phase 2 · registry result, not featured evidence · combination
—Stage 2 (Cohort 2A): Niraparib + T
NCT03308942 · Phase 2 · registry result, not featured evidence · combination
28.2%b
NCT03607539 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
show 2 more results
38.9%
NCT03150875 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
50.3%
NCT03629925 · Phase 3 · registry result, not featured evidence · combination
Most frequent reported AEs
a
anaemia 34.8%
neutropenia 31.5%
fatigue 29.5%
NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3
show 2 more results
anaemia 31.5%
fatigue 29.8%
diarrhoea 29.5%
NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3
nausea 58.3%
diarrhoea 50%
fatigue 41.7%
NCT03308942 · Phase 2 · registry result, not featured evidence · combination
b
anaemia 74.1% (placebo 78.6%)
neutrophil count decreased 71.1% (placebo 62.6%)
white blood cell count decreased 67.7% (placebo 64.1%)
NCT03607539 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
show 2 more results
anaemia 33.3%
decreased appetite 23.6%
pyrexia 21.5%
NCT03150875 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
anaemia 93.3% (placebo 90.4%)
white blood cell count decreased 88.8% (placebo 86%)
neutrophil count decreased 83.2% (placebo 82%)
NCT03629925 · Phase 3 · registry result, not featured evidence · combination

Notes

  1. aPopulation comparability has not been reviewed for 2 of these studies.
  2. bPopulation comparability has not been reviewed for 1 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Dostarlimab

Overall Survival 11.9 months
time to event · months
No placebo or comparator arm
NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3
show 1 more result
11.8 months
NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3
ORR 9.1% (n=11)
responder rate · % of participants
No placebo or comparator arm
NCT03308942 · Phase 2 · registry result, not featured evidence · combination
Duration of Response 21.5 months
time to event · months
No placebo or comparator arm
NCT03308942 · Phase 2 · registry result, not featured evidence · combination
Disease Control 54.5% (n=11)
responder rate · % of participants
No placebo or comparator arm
NCT03308942 · Phase 2 · registry result, not featured evidence · combination
PFS 4.4 months
time to event · months
No placebo or comparator arm
NCT03308942 · Phase 2 · registry result, not featured evidence · combination

Sintilimab

Disease Control 86.8% (n=266) vs 75.6% (n=131) placebo
responder rate · % of participants
NCT03607539 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
show 1 more result
86% (n=179) vs 80.3% (n=178) placebo
NCT03629925 · Phase 3 · registry result, not featured evidence · combination
Time to Response 1.51 vs 2.63 placebo months
time to event · months
NCT03607539 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
show 1 more result
1.41 vs 1.41 placebo months
NCT03629925 · Phase 3 · registry result, not featured evidence · combination

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Dostarlimab's landscape · Sintilimab's landscape